SEC Form 4 · accession 0001209191-19-011089
Karyopharm Therapeutics Inc. · KPTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anand Varadan
Officer — EVP, Chief Commercial Officer
Period of report
Feb 15, 2019
Accepted (ET)
Feb 19, 2019 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.21 | Feb 15, 2019 | A | 102,800 | A | — | Feb 14, 2029 | Common Stock | 102,800 | 102,800 | D |
| Restricted Stock UnitsF2,F3 | — | Feb 15, 2019 | A | 38,700 | A | — | — | Common Stock | 38,700 | 38,700 | D |
Explanation of responses
- F1This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- F2Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.
- F3The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.